Brokerages Set Agilent Technologies Inc (NYSE:A) PT at $84.27

Shares of Agilent Technologies Inc (NYSE:A) have been given an average rating of “Hold” by the eighteen research firms that are currently covering the stock, MarketBeat reports. Nine investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $84.80.

A number of analysts have commented on the stock. Zacks Investment Research raised shares of Agilent Technologies from a “sell” rating to a “hold” rating and set a $89.00 price objective for the company in a research note on Friday, February 21st. Wells Fargo & Co assumed coverage on shares of Agilent Technologies in a research note on Tuesday, January 7th. They set an “overweight” rating and a $100.00 price objective for the company. JPMorgan Chase & Co. upped their price objective on shares of Agilent Technologies from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Tuesday, November 26th. HSBC raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Wednesday, February 12th. Finally, Needham & Company LLC lowered shares of Agilent Technologies from a “buy” rating to a “hold” rating and set a $85.00 price objective for the company. in a research note on Monday.

A traded down $0.36 on Friday, reaching $77.07. The company had a trading volume of 3,755,580 shares, compared to its average volume of 2,064,175. The company has a fifty day moving average of $85.83 and a 200-day moving average of $79.37. The company has a market capitalization of $24.23 billion, a P/E ratio of 31.85, a PEG ratio of 1.83 and a beta of 1.41. The company has a current ratio of 1.64, a quick ratio of 1.27 and a debt-to-equity ratio of 0.37. Agilent Technologies has a one year low of $65.35 and a one year high of $90.64.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Tuesday, February 18th. The medical research company reported $0.81 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.81. Agilent Technologies had a net margin of 14.59% and a return on equity of 20.49%. The company had revenue of $1.36 billion during the quarter, compared to the consensus estimate of $1.36 billion. During the same period in the prior year, the company earned $0.76 EPS. Agilent Technologies’s revenue was up 5.7% on a year-over-year basis. Research analysts predict that Agilent Technologies will post 3.41 EPS for the current year.

In other news, CEO Michael R. Mcmullen sold 24,636 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $82.90, for a total value of $2,042,324.40. Following the completion of the sale, the chief executive officer now directly owns 332,121 shares of the company’s stock, valued at $27,532,830.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Dominique Grau sold 15,000 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $82.85, for a total value of $1,242,750.00. Following the completion of the sale, the senior vice president now directly owns 97,498 shares of the company’s stock, valued at $8,077,709.30. The disclosure for this sale can be found here. In the last quarter, insiders have sold 65,049 shares of company stock worth $5,499,936.

Several institutional investors and hedge funds have recently bought and sold shares of A. First Bank & Trust bought a new position in Agilent Technologies in the fourth quarter worth $29,000. Citizens Financial Group Inc RI lifted its position in Agilent Technologies by 260.0% in the fourth quarter. Citizens Financial Group Inc RI now owns 360 shares of the medical research company’s stock worth $31,000 after purchasing an additional 260 shares during the period. FinTrust Capital Advisors LLC lifted its position in Agilent Technologies by 450.7% in the fourth quarter. FinTrust Capital Advisors LLC now owns 380 shares of the medical research company’s stock worth $32,000 after purchasing an additional 311 shares during the period. Liberty Wealth Management LLC bought a new position in Agilent Technologies in the fourth quarter worth $52,000. Finally, Whittier Trust Co. of Nevada Inc. lifted its position in Agilent Technologies by 50.1% in the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 707 shares of the medical research company’s stock worth $60,000 after purchasing an additional 236 shares during the period.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

See Also: Rule of 72

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.